Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...
A new family of microcontrollers (MCUs) —the PIC24FJ128GC010 -- is an analog system on chip that integrates an on-chip precision 16-bit ADC and 10 Msps 12-bit ADC, plus a DAC and dual operational ...
Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...
Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results